Women’s health doctors and researchers will share new insights on prenatal care
The Icahn School of Medicine at Mount Sinai Health System is spearheading a collaborative effort to investigate dupilumab as a treatment for children with alopecia areata, a disease that causes extensive hair loss.
Top honor recognizes her commitment to justice, equity, diversity, and inclusion through scholarship, mentorship, and leadership
Researchers at the Icahn School of Medicine at Mount Sinai have made a significant discovery, identifying genetic connections between inflammatory bowel disease (IBD) and Parkinson’s disease (PD). Published in Genome Medicine on May 13, their study highlights the potential for joint therapeutic strategies to target these two challenging disorders.
Researchers at the Icahn School of Medicine at Mount Sinai have shed valuable light on the complex mechanisms by which a class of psychedelic drugs binds to and activates serotonin receptors to produce potential therapeutic effects in patients with neuropsychiatric disorders such as depression and anxiety.
Twenty years ago today, the East Harlem Health Outreach Partnership (EHHOP) at Mount Sinai opened its doors, creating a new model of community service and patient care. EHHOP, a free student-run, physician-supervised clinic, serves approximately 300 residents of East Harlem every year.
Miriam Merad, MD, PhD, a world-renowned immunologist, has been appointed Dean for Translational Research and Therapeutic Innovation of the Icahn School of Medicine at Mount Sinai. The appointment reaffirms Icahn Mount Sinai’s commitment to pioneering medical progress and catalyzing the rapid advancement of research innovation. Dr. Merad, the Mount Sinai Professor in Cancer Immunology, will also continue to serve as the founding Chair of the Department of Immunology and Immunotherapy, Director of the Marc and Jennifer Lipschultz Precision Immunology Institute, and Director of the Human Immune Monitoring Center. As Dean, Dr. Merad aims to elevate early clinical trials at Icahn Mount Sinai, streamline the clinical trial process, cultivate a culture of mechanistic clinical trials throughout the campus, and forge stronger partnerships with the pharmaceutical and biotech sectors.
Study identifies key pathways underlying perianal fistula, a disease complication that is more prevalent and severe in African Ameri can populations
In a scientific breakthrough, Mount Sinai researchers have revealed the biological mechanisms by which a family of proteins known as histone deacetylases (HDACs) activate immune system cells linked to inflammatory bowel disease (IBD) and other inflammatory diseases.
State-of-the-art artificial intelligence systems known as large language models (LLMs) are poor medical coders, according to researchers at the Icahn School of Medicine at Mount Sinai.
Mount Sinai scientists, in collaboration with researchers from the Carlos III Health Institute (ISCIII) in Madrid, Spain, have located and identified alterations in the monkeypox virus genome that potentially correlate with changes in the virus’s transmissibility observed in the 2022 outbreak.
Mount Sinai researchers, in collaboration with scientists at The Rockefeller University, have uncovered a mechanism in the brain that allows cocaine and morphine to take over natural reward processing systems.
Mount Sinai Health System today announced that it has been named one of Modern Healthcare’s Innovators for 2024, an award that recognizes leaders and organizations driving innovation that improves care, achieves measurable results, and contributes to the clinical and financial goals of the organization.
Mount Sinai Health System leaders will attend and present at the International Forum for Quality and Safety in Healthcare 2024, a preeminent healthcare quality event organized by the Institute for Healthcare Improvement (IHI) and British Medical Journal (BMJ) on April 11th at ExCel London, United Kingdom.
Breakthrough study led by Mount Sinai researcher could change standard-of-care guidelines to improve outcomes
Mount Sinai-led study identifies type of heart failure for which device may be most useful
A Medicare policy requiring primary care providers (PCPs) to share in the decision-making with patients on whether to proceed with lung cancer screening is fraught with confusion and lack of evidence-based information, and may actually be undermining the purpose for which it was created, Mount Sinai researchers say.
A multidisciplinary team of neurosurgeons and neuroscientists from the Icahn School of Medicine at Mount Sinai are the first in New York to study a new brain-computer interface that’s engineered to map a large area of the brain’s surface, in real time, at resolutions hundreds of times more detailed than typical arrays used in neurosurgical procedures.
Using novel genetic and genomic tools, researchers at the Icahn School of Medicine at Mount Sinai have shed light on the role of immune cells called macrophages in lipid-rich tissues like the brain, advancing our understanding of Alzheimer’s and other diseases.
Researchers available for interview about their new studies and other women’s health topics
Warning follows Mount Sinai’s landmark eye damage case linked to the 2017 eclipse
Rosalind J. Wright, MD, MPH, appointed inaugural Dean for Public Health and Chair of the new Department of Public Health to spearhead a state-of-the-art curriculum in public health research, education, and practice that will systematically integrate with medicine, population health, global health, neurosciences, environmental medicine, data science and Artificial Intelligence (AI) disciplines.
The Icahn School of Medicine at Mount Sinai announced today the establishment of the Institute for Equity and Justice in Health Sciences Education. The Institute will expand upon Icahn Mount Sinai’s anti-racist, anti-biased learning and training environment in medical and graduate education.
Team studying predictive models for serious sleep condition awarded $3 million NIH grant
Researchers at the Icahn School of Medicine at Mount Sinai and others have harnessed the power of machine learning to identify key predictors of mortality in dementia patients. The study, published in the February 28 online issue of Communications Medicine, addresses critical challenges in dementia care by pinpointing patients at high risk of near-term death and uncovers the factors that drive this risk. Unlike previous studies that focused on diagnosing dementia, this research delves into predicting patient prognosis, shedding light on mortality risks and contributing factors in various kinds of dementia.
New study results challenge the idea that vaccine immunity fades quickly
Recent developments in cancer research have highlighted the vital role of the immune system, particularly in the notable successes of cancer immunotherapy. Now, a paradigm-shifting study led by researchers at the Icahn School of Medicine at Mount Sinai in New York in collaboration with the University of Helsinki and Massachusetts General Hospital sheds light on how variations in immune genetics influence lung cancer risk, potentially paving the way for enhanced prevention strategies and screening. The findings were described in the February 22 online issue of Science.
Research shows this tool can strongly support clinicians for patient care
Funding will also support researching other complex illnesses and medical education
World leader in aortic valve reconstruction is first Mount Sinai surgeon to lead the international organization
Results from this large-scale synthesis of all prior clinical trials could increase usage of several types of high-resolution imaging for guiding interventional coronary procedures
Results of 16-Center REVIVE trial published in The New England Journal of Medicine
Physicians from the Department of Rehabilitation and Human Performance will play a key role in preparing athletes for tournaments
High-risk pregnancy specialists from the Mount Sinai Health System are presenting research at the Annual Pregnancy Meeting of the Society for Maternal-Fetal Medicine (SMFM) from February 10-14
Researchers from the Icahn School of Medicine at Mount Sinai, in collaboration with the Clinical Proteomic Tumor Analysis Consortium of the National Institutes of Health, The University of Texas MD Anderson Cancer Center, Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, and others, have unveiled a detailed understanding of immune responses in cancer, marking a significant development in the field. The findings were published in the February 14 online issue of Cell. Utilizing data from more than 1,000 tumors across 10 different cancers, the study is the first to integrate DNA, RNA, and proteomics (the study of proteins), revealing the complex interplay of immune cells in tumors. The data came from the Clinical Proteomic Tumor Analysis Consortium (CPTAC), a program under the National Cancer Institute.
The Icahn School of Medicine at Mount Sinai announced today the appointment of David C. Thomas, MD, MS, MHPE, as Dean of Medical Education and Chair of the Department of Medical Education.
Study shows using advanced technology and time can prevent permanent vision loss
The Mount Sinai Recanati/Miller Transplantation Institute has received a $5 million gift from the Blavatnik Family Foundation, pledged across five years.
Mount Sinai research could lead to more consistency and safety measure.
Work will facilitate interdisciplinary study of feelings, emotions, moods, and other sensory experiences, as well as the development of treatments for mental disorders.
Machine-learning method aims to predict consequences of serious sleep disorder impacting millions in the U.S.
Findings shed light on mechanisms underlying psychosocial stress and depression susceptibility
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
